Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Does The Market Size Of The Intermittent Claudication Industry Compare Between 2025 And 2029?
The intermittent claudication market has shown significant growth in recent years. It is anticipated to expand from $12.81 billion in 2024 to $13.51 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.5%. This historical expansion is attributable to several factors, including a rise in peripheral artery disease, increased awareness regarding vascular diseases, growth in the geriatric population, higher diagnosis rates, and an increase in healthcare expenditure.
The market size for intermittent claudication is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $16.99 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period can be attributed to factors such as the increasing prevalence of diabetes, rising rates of obesity, a growing incidence of cardiovascular diseases, elevated alcohol and tobacco consumption, and increased healthcare spending. Key trends expected in this period include advancements in pad diagnostics, the integration of wearable devices, the adoption of personalized medicine, a move towards drug-eluting stents, and progress in stem cell therapy.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp
Which Drivers Are Impacting The Intermittent Claudication Market?
A surge in peripheral artery disease (PAD) cases is anticipated to stimulate the expansion of the intermittent claudication market moving forward. Peripheral artery disease is defined as a circulatory disorder where arteries narrow, decreasing blood flow to the limbs, which can cause pain, numbness, and further complications. The increasing incidence of peripheral artery disease is attributed to factors like an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. PAD contributes to intermittent claudication by diminishing blood flow to leg muscles during exertion, resulting in pain and cramping from a lack of oxygen. For instance, in June 2023, as per the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, peripheral artery disease (PAD) impacts 7-12 million in the U.S. and 200 million globally. Hence, the rising number of peripheral artery disease (PAD) cases is a key driver for the growth of the intermittent claudication market.
What Are The Different Segment Classifications Within The Intermittent Claudication Market?
The intermittent claudicationmarket covered in this report is segmented –
1) By Type: Medication Therapies; Revascularization
2) By Route Of Administration: Parenteral Route; Oral Route; Other Routes Of Administration
3) By Application: Hospitals; Clinics; Home Healthcare; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Medication Therapies: Antiplatelet Agents; Vasodilators; Phosphodiesterase Inhibitors; Cilostazol; Pentoxifylline
2) By Revascularization: Angioplasty; Stenting; Bypass Surgery; Endarterectomy
What Long-Term Trends Will Shape The Future Growth Of The Intermittent Claudication Industry?
Leading companies within the intermittent claudication market are increasingly focusing on developing advanced medicinal therapies, such as RIPK1 inhibitors, to improve treatment outcomes for individuals suffering from peripheral artery disease (PAD) accompanied by intermittent claudication. The aim of these innovations is to enhance blood circulation, alleviate inflammation, and halt disease progression. RIPK1 inhibitors are specifically designed drugs that work by blocking RIPK1 kinase activity, which consequently diminishes inflammation and cell death. An example of this trend is seen in August 2022, when GenFleet, a biotechnology firm based in China, obtained approval from the US Food and Drug Administration (FDA) to commence a Phase II clinical trial for GFH312. This particular therapy is an innovative solution for peripheral artery disease (PAD) with intermittent claudication (IC). The upcoming study, designed as a randomized, double-blinded, placebo-controlled trial, is planned to be carried out across 15 research centers. GFH312, a RIPK1 inhibitor, has previously demonstrated encouraging results in preclinical investigations by effectively suppressing the inflammatory response observed in animal models.
Which Key Players Are Driving Competition In The Intermittent Claudication Market?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report
Which Region Shows The Highest Potential For Future Expansion In The Intermittent Claudication Market?
North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Intermittent Claudication Market Report:
https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp
Browse Through More Reports Similar to the Global Intermittent Claudication Market 2025, By The Business Research Company
Intermittent Catheters Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/intermittent-catheters-global-market-report
Intermittent Pneumatic Compression Ipc Devices Global Market Report 2025
Coronary Artery Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model